IRMD IRADIMED CORPcompanySEC Filings & Insider Trading Activity 2026
Latest IRADIMED CORP (IRMD) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 6, 2026, a 10-Q quarterly report filed on November 3, 2025, an 8-K current report filed on May 1, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for IRADIMED CORP (IRMD) (SEC CIK 1325618), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business: Development and sale of MRI compatible medical devices, notably IV infusion pumps and patient vital signs monitors for safe MRI environment use
- • New product emphasis: MRidium 3870 MRI Compatible IV Infusion Pump System launched in 2025 with Remote Display Unit for control from MRI control room
Risk Factors
- • FDA regulatory risk: potential refusal or revocation of 510(k) clearances affecting MRidium infusion pumps and 3880 patient monitors
- • Geopolitical risk: supply chain disruption from tariffs, trade restrictions, and political instability impacting sourcing of proprietary raw materials
Management Discussion & Analysis
- • Revenue $83.8M in 2025, up 14.4% YoY from $73.2M in 2024, driven by U.S. sales +$10.0M (16.4%) and international sales +$0.6M (4.8%)
- • Operating margin 31.2% in 2025 vs 30.0% in 2024; gross profit margin stable at 77% both years
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Management Discussion & Analysis
- • Revenue $21.2M for Q3 2025, up 16% YoY from $18.3M in Q3 2024; nine months revenue $61.1M, up 13% from $53.9M
- • Gross margin 78% Q3 2025 vs 77% Q3 2024; nine months margin steady at 77% both years
Risk Factors
- • No newly added risk factors disclosed this quarter; section continues prior risks without material updates
- • Most materially updated risk: increased regulatory expenses driven by expanded FDA requirements and ongoing post-market surveillance programs
Annual Reports Archive10-K
AI-powered analysis of IRADIMED CORP (IRMD) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of IRADIMED CORP (IRMD) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $53.3M | $65.6M | $73.2M | $83.8M |
| Gross Profit | $41.3M | $50.2M | $56.3M | $64.3M |
| Operating Income | — | $20.0M | $22.0M | $26.1M |
| Net Income | — | $17.2M | $19.2M | $22.5M |
| Gross Margin | 77.4% | 76.5% | 76.9% | 76.7% |
| Op. Margin | — | 30.6% | 30.0% | 31.2% |
| Net Margin | — | 26.2% | 26.3% | 26.8% |
| Balance Sheet | ||||
| Total Assets | — | $92.2M | $98.3M | $108.8M |
| Equity | — | $71.4M | $86.8M | $94.6M |
| ROE | — | 24.1% | 22.2% | 23.8% |
Source: XBRL financial data from IRADIMED CORP (IRMD) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | May 1, 2026 | — | — | — |
10-K | Mar 6, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 10, 2026 | — | — | |
8-K | Dec 8, 2025 | — | — | |
10-Q | Nov 3, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 1, 2025 | Jun 30, 2025 | — | |
10-Q | May 5, 2025 | Mar 31, 2025 | — | |
10-K | Mar 6, 2025 | Dec 31, 2024 | — | |
10-Q | Oct 31, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 2, 2024 | Mar 31, 2024 | — | |
10-K | Mar 1, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 3, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 3, 2023 | Jun 30, 2023 | — | |
10-Q | May 4, 2023 | Mar 31, 2023 | — | |
10-K | Mar 2, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 5, 2022 | Jun 30, 2022 | — | |
10-Q | May 6, 2022 | Mar 31, 2022 | — | |
10-K | Mar 4, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 5, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 6, 2021 | Jun 30, 2021 | — | |
10-Q | May 7, 2021 | Mar 31, 2021 | — | |
10-K | Mar 5, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 6, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest IRMD SEC filings in 2026?
IRADIMED CORP (IRMD) has filed a 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 3, 2025, an 8-K current report on May 1, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did IRMD file its most recent 10-K annual report?
IRADIMED CORP (IRMD) filed its most recent 10-K annual report on March 6, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view IRMD 10-Q quarterly reports?
IRADIMED CORP (IRMD)'s most recent 10-Q quarterly report was filed on November 3, 2025. SignalX displays every IRMD 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has IRMD filed recently?
IRADIMED CORP (IRMD)'s most recent 8-K was filed on May 1, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find IRMD insider trading activity (Form 4)?
SignalX aggregates every IRMD Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does IRMD file with the SEC?
IRADIMED CORP (IRMD) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IRMD filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for IRADIMED CORP (IRMD).
What is IRMD's SEC CIK number?
IRADIMED CORP (IRMD)'s SEC CIK (Central Index Key) number is 1325618. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1325618 to look up all IRMD filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find IRMD return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from IRADIMED CORP (IRMD) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of IRADIMED CORP SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 50+ filings.